Earnings Summary

Neogenomics, Inc.’s revenue jumped 17.47% since last year same period to $146.92Mn in the Q2 2023. On a quarterly growth basis, Neogenomics, Inc. has generated 7.07% jump in its revenue since last 3-months.

Neogenomics, Inc.’s net profit jumped 31.08% since last year same period to $-24.33Mn in the Q2 2023. On a quarterly growth basis, Neogenomics, Inc. has generated 20.99% jump in its net profits since last 3-months.

Neogenomics, Inc.’s net profit margin jumped 41.33% since last year same period to -16.56% in the Q2 2023. On a quarterly growth basis, Neogenomics, Inc. has generated 26.21% jump in its net profit margins since last 3-months.

Neogenomics, Inc.’s earning per share (EPS) estimates for the current quarter stand at -0.16 - a 23.81% jump from last quarter’s estimates.

Neogenomics, Inc.’s earning per share (EPS) estimates for the current year stand at -0.16.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Neogenomics, Inc.’s return on assets (ROA) stands at -0.04.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Neogenomics, Inc.’s return on equity (ROE) stands at -0.11.